FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Pfizer | Lipitor | Jeffrey Kindler

Pfizer CEO open to big buyout deals

Tools

In an interview with the Financial Times, Pfizer CEO Jeff Kindler said the company is willing to acquire a large rival drugs company to improve its financial health, in a move that could trigger a fresh round of mergers within the sector. "The real goal is to grow revenues...We are open to opportunities and constantly looking at those which are big, small and in between," Kindler said in an interview. Pfizer is bracing itself to the expiration of Lipitor's patent protection in 2011; a major deal could help the company fill the $13-billion-a-year void the drug's patent expiration will cause. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Email Newsletter:

More stories about Pfizer   Lipitor   Jeffrey Kindler